Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.

International journal of cancer - 1 Feb 2002

Galmarini Carlos María, Clarke Marilyn L, Falette Nicole, Puisieux Alain, Mackey John R, Dumontet Charles

Abstract excerpt

Gemcitabine is a relatively new agent with promising activity in solid tumors. Few data are available regarding mechanisms of resistance to gemcitabine downstream from the drug-target interaction. The present study was performed to gain insight into the role of p53 status on the cytotoxicity of gemcitabine on cancer cells. Drug sensitivity, drug metabolism, cell kinetics and drug-induced apoptosis were compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to bcl-X Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to G1 Phase

Share to Gemcitabine

Share to Genes, bcl-2

Share to RNA, Neoplasm

Share to S Phase

Source

Identifiers

PMID: 11802204
DOI: 10.1002/ijc.1628

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.PMID 11802204Read ↗

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.Semantic proximity Read ↗

Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.Semantic proximity Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.Semantic proximity Read ↗

The dual role of mutant p53 protein in chemosensitivity of human cancers.Semantic proximity Read ↗

Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors.Semantic proximity Read ↗

Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.Semantic proximity Read ↗

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3Semantic proximity Read ↗

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated CellsSemantic proximity Read ↗

Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.Semantic proximity Read ↗

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.